Member Info for Jarv55

Boxerdog is a smart guy holding all his shares that is dilution.

What did you work with him on?

News soon hopefully

Ignore the noise buy the dip https://invst.ly/spm-k any contract news and this share is multibagging.

Bouncing back now https://invst.ly/spm6o

Added a few here

more cash on the balance sheet
4 November 2020

Remote Monitored Systems plc ("RMS" or the "Company")

Exercise of warrants

The Company has received notification to exercise a further 6,000,000 warrants at an exercise price of 0.5p each. The consideration received by the Company will be £30,000.



The 6,000,000 new Ordinary Shares ("Shares") arising from the exercise of these warrants have now been issued, and application has been made for them to be admitted to trading on AIM ("Admission"). It is expected that Admission will become effective and dealings will commence at 8:00a.m. on or around 11 November 2020.



Following Admission, the Company will have 1,502,627,261 ordinary shares of 0.01p each in issue, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 1,502,627,261.



The above figure of 1,502,627,261 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

Breaking out https://invst.ly/spkll

News can land anytime from today
Further to the announcement of 19 October 2020, Braveheart notes that the conditional sale of its 51.72% holding in Pharm 2 Farm Limited to Remote Monitored Systems plc ("RMS") is expected to complete on 5 November 2020 (the "Sale"). The Sale is subject to, amongst other things, the passing of the resolutions, including the resolution seeking approval of the whitewash of Braveheart's Rule 9 obligations by the independent shareholders of RMS, at the General Meeting of RMS being held on 4 November 2020.

News can land any time from today
Further to the announcement of 19 October 2020, Braveheart notes that the conditional sale of its 51.72% holding in Pharm 2 Farm Limited to Remote Monitored Systems plc ("RMS") is expected to complete on 5 November 2020 (the "Sale"). The Sale is subject to, amongst other things, the passing of the resolutions, including the resolution seeking approval of the whitewash of Braveheart's Rule 9 obligations by the independent shareholders of RMS, at the General Meeting of RMS being held on 4 November 2020.

The chart is set up beautifully for a rise 34ema and 8ema cross over incoming going through the 50ma, gap to fill at 2.17
https://invst.ly/spk1c

Do remember that they are lobbying the goverment and aleady sellling to the nhs no wonder brh are holding onto these shares.

The directors of Braveheart believe that by combining the two shareholdings of P2F in RMS, and thereafter retaining a significant interest in RMS, the business prospects for P2F can be more rapidly exploited and resourced, thus enabling Braveheart to continue having an economic interest in P2F without the continuing requirement to fund P2F. The directors of Braveheart intend to retain the Consideration Shares for the foreseeable future. The directors of RMS believe that the Acquisition is in the interest of RMS shareholders, the proposed price to be paid and its settlement in new equity of the Company is fair and reasonable, based upon the Company’s assessment of the significant potential of the Pharm2Farm business and the potential upside for shareholders if P2F can successfully execute its plans. The directors

Just chilling waiting for the news flow to start bags to come here. GLA LONGS

In addition Pharm2Farm’s modular platform technology and flat organisational structure provides the agility and flexibility to respond to the specific needs of each market segment. Hence, Pharm2Farm is able to capture very high value – low volume markets such as in electronics. Pharm2farm’s main competitor (Promethean) which has a large 1,000MT inefficient reactor requires large minimum order sizes to be profitable. Looking at the face mask market alone: global face mask market was valued at $1.52 billion in 2019 and is expected to grow by 4.4% CAGR reaching $2.45 billion in 2027. Pharm2Farm’s Innovate UK project is expected to produce a higher value anti- viral face mask prototype by December 2020.

https://amp.theguardian.com/society/2020/nov/03/45m-deal-for-nhs-masks-collapses-amid-claims?__twitter_impression=true

This tech can be licensed out think about it. https://www.insider.co.uk/news/honeywell-create-70-million-face-22030794

Of course there are others making antiviral masks but just like testing there are lots of different tests, we are in a pandemic where everything needs to be thrown at it.

doctorv and where do you buy these masks in the uk?

I am sure we are going to get all kinds of idiots turning up telling us to sell you just have to ignore the noise, they know this could be big and want a cheaper entry, know what you own. I expect I will be seeing a lot of green.

Think Trump will win